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Sublingual immunotherapy is currently considered a viable alternative to the subcutaneous route. The body of
evidence of its efficacy is based on the results of 77 clinical trials and 7 meta-analyses, that have been published so
far. Nonetheless, the experimental evidence is partially weak due to the large heterogeneity of studies, namely:
doses, regimens, patient selection, duration of treatment, outcomes and reporting. In addition, it is virtually
impossible to compare the potency of extracts produced by different manufacturers. Also, there is large variability
in reporting and in the classification of adverse events, either systemic or local, so that only a rough estimate can
be provided. Considering all these aspects, efforts are needed to harmonize the methodology, outcome measures
and reporting of SLIT clinical trials, to achieve the ability of comparing the results of various studies. International
societies and the World Allergy Organization have recently provided general recommendations on how to design
and conduct trials which can provide more interpretable and homogeneous data.Introduction and background
The subcutaneous modality of specific immunotherapy
(SCIT) remained for many decades the only available
route of administration for allergen immunotherapy. SCIT
is effective and safe, when properly prescribed and adminis-
tered, but a certain level of risk of severe side effects still re-
mains [1]. The problem of the risk/benefit ratio prompted,
mainly during the 1980’s, the search for safer routes of ad-
ministration, among which, the sublingual one (SLIT), first
described in 1986, achieved both scientific and clinical im-
portance. In less than 25 years since the first report, SLIT
gained credibility, and was therefore introduced in the offi-
cial documents as a viable alternative to the classic injection
route [2,3] for both adults and children. Presently, SLIT is
commercialized and routinely used in Europe and in many
other countries, and some products have also been ap-
proved recently in the USA.
According to the more recent World Allergy
Organization (WAO) Position Paper on SLIT [4], there
are 77 randomized placebo controlled trials published,
of which only 8 have demonstrated negative results.
Some studies have clearly shown a dose-dependent
effect of SLIT [5,6], indicating robust support in favor ofCorrespondence: passalacqua@unige.it
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unless otherwise stated.its clinical efficacy. Due to the large number of trials
available, several meta-analyses have been carried out
(Table 1), with various inclusion criteria such as rhinitis
and asthma [7,8], asthma only [9], asthma and/or rhin-
itis in children [10,11], conjunctivitis [12]. Moreover,
separate meta-analyses for single allergens such as dust
mite [13] or grasses [14] have also been published, with
favorable results as well. On the other hand, the validity
of the meta-analyses remains limited by the high degree
of statistical heterogeneity as a result of the heterogen-
eity of the studies themselves. Main sources of hetero-
geneity are: criteria of inclusion, sample size, duration
of treatment, administration regimens, maintenance dose,
standardization of extracts, outcomes, reporting, and the
description of adverse events. Table 2 evidences the main
variability aspects. All these elements make the trials diffi-
cult to compare.
In the last decade, several “large trials” (involving
hundreds of patients) were performed and published [4].
These trials provided the evidence and suggested the
need for a more uniform design and conduction of
clinical studies, in order to harmonize and compare the
results obtained, so that robust recommendations can be
given. Of note, the methodological problems had been
well recognized; therefore recommendations for a better
standardization of clinical trials were published and dis-
seminated [15-17].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Meta analyses of slit randomized controlled trials
Author Population Disease* Active/Placebo SMD** Heterogeneity I2
Wilson et al. [7] Adults + Children R 484/475 −0.42 73%
Penagos et al. [10] Children < 18 y R 245/239 −0.56 81%
Calamita et al. [9] Adults + children A 150/153 −0.38 64%
Penagos et al. [11] Children < 18 y A 232/209 −1.14 92%
Compalati et al. [13] Adults + children only mite RAC 194/188 −0.95 92%
Di Bona et al. [14] Adults + children only grass RAC 1518/1453 −0.32 56%
Radulovic et al. [8] Adults + children R 2333/2256 −0.49 81%
Calderon et al. [12] Adults + children C 1725/1674 −0.41 59%
*R = rhinitis, A = asthma; C = conjunctivitis. **SMD = standardized mean deviation. ***Heterogeneity (very high when I2 > 75%).
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Design
Certainly, it is mandatory that a placebo comparison and
a double blind design are used. This is to allow the meas-
urement of the magnitude/size of the effects of SLIT over
the non-SLIT group. It has to be kept in mind that, usu-
ally, the SLIT trials are not truly placebo controlled (that
would be only SLIT versus only placebo), as all patients
are allowed to use rescue or regular medications for their
symptoms (antihistamines, nasal steroids, bronchodilators
etc.). Indeed, SLIT is used as an add-on treatment to res-
cue medications and it is placebo-controlled in this sense.
In addition the placebo effect is usually relevant in im-
munotherapy trials [18]. Another interesting aspect is that
no “equivalent” placebo is available for SLIT, since the
local side effects (oral itching, burning, swelling, nausea)
cannot be mimicked by a placebo substance. Thus, sub-
jects who are receiving the active treatment in such set-
tings can be quite easily identified by investigators, also
considering that the local side effects by the active SLIT
usually disappear after 5–10 days [19]. Nonetheless, it is
also true that appropriate sub-analyses showed that the
possible placebo-unblinding due to local side effects did
not affect the validity of results [20]. It is clear that a pla-
cebo should at least have the same appearance, taste and
smell as the active formulation, but presently it is not feas-
ible to have a totally equivalent placebo [16].
Patients and exposure
SLIT is allergen-specific, therefore the sensitization to
the offending allergen should be clearly demonstrated by
the usual standard diagnostic techniques, as well as theTable 2 Main characteristics of the 77 randomized controlled
Allergen Grass Dust mite
34 20
Duration < 6 months 6-12 months
31 21
Patients <50 51-100
32 21causal role of the culprit allergen in inducing symptoms.
Monosensitized subjects would be the ideal patients, but
in real life the vast majority of patients are polysensi-
tized. On the other hand, it has been shown that, when
the causal role of an allergen in inducing symptoms is
clearly established and documented, the concomitance
of other sensitizations does not affect in general the effi-
cacy of SLIT [21]. Another important aspect is that pa-
tients should be symptomatic at the beginning of the
study (or during the selection phase or baseline evalu-
ation). If patients have only mild or intermittent symp-
toms (asthma/rhinitis), an add-on effect is difficult to
detect. This was clearly demonstrated by two studies in
asthmatic patients [22,23]. In both studies, no effect of
SLIT could be demonstrated in asthma versus baseline,
and placebo, but in both studies patients were already
optimally controlled by therapy at baseline.
As mentioned above, the exposure to the culprit aller-
gen should be well documented. This is expensive and
difficult to apply with dust mite or pet dander, provided
that appropriate avoidance measures are applied to all
recruited patients. For plant-derived allergens, detailed
pollen counts are available almost everywhere. Thus,
pollen counts pertinent to the area where the patients live
should be provided, and data should be normalized ac-
cording to pollen count itself (e.g. peak pollen period) for
a given area, that may differ in multicenter studies, as
shown in recent large trials [24].
Outcome, sample size, statistical aspects
As happens for traditional drug trials, the primary out-
come must be clearly defined, since it defines the sampletrials of SLIT
Parietaria Ragweed Others
5 5 13
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debate on the fact that intent to treat (ITT) population
should be analyzed. Due to the delayed effects of SLIT,
and the need that treatment is assumed for long times, a
per protocol analysis also can be justified. All post-hoc
analyses must be appropriately declared in the study
design [15-17].
Rhinitis symptoms are traditionally measured by a
grading that ranges from 0 (absent) to 3 (bothersome)
for rhinorrhea, obstruction, sneezing, itching (two or three
conjunctival symptoms using the same scale are often
added) [25]. Probably, the Visual Analog Scale (VAS) sys-
tem could replace the traditional categorical scoring [26].
Since symptoms may depend on the use of medications, a
combined symptoms +medication score is recommended
as the primary outcome [16,17]. A reduction of that score
greater than 20% versus placebo is considered reasonably
significant. Recently, an adjusted score considering day-
by-day the effect of drugs has been proposed [27].
Regimens and doses
The regimen of administration and maintenance dose, as
described in the literature, largely varies among the
different manufacturers. The dose of allergen adminis-
tered still represents the main obstacle for a well defined
harmonization. In fact, each producer standardizes the
vaccine according to an in-house reference. The result is
that the real amount of allergen(s) contained in each
preparation largely varies [28]. In recent years, attempts
have been made to have a uniformity in the potency of ex-
tracts by expressing the content of allergens in mcg/mL.
This has resulted in the ability to perform dose-ranging
trials which provided consistent results for grasses in dif-
ferent trials [5,6], but similar data are still needed for other
relevant allergens.
In addition, the administration protocols largely vary
among manufacturers. The clinical efficacy of SLIT was
demonstrated with tablets, drops or sublingual sprays
administered either daily, every other day or twice weekly
[29]. For seasonal allergens, although the continuous (all-
year long) administration have been shown to be effective
also in the long term [24], there is evidence that a pre
(−coseasonal) regimen may be equally effective as well
[30,31]. A standardization of doses and administration
regimens is urgently needed to clearly assess the efficacy
of the treatment and to compare studies and products.
Safety monitoring
Safety is an essential aspect of SLIT, because it was de-
signed especially to overcome the possible systemic side
effects of SCIT as described in several reviews. Nonethe-
less, the description of safety in clinical trials and post-
marketing surveys is variable and sometimes vague, so
that a uniform and comprehensive evaluation cannotstill be made. It is true that SLIT has, in general, a better
safety profile than SCIT [4], but the reporting of adverse
events remains largely subjective. In the majority of tri-
als, the traditional EAACI grading system for the sever-
ity of systemic side effects was used see [32], although in
the case of SLIT, systemic effects are rare, whereas local
side effects are common. For these reasons, it has been
agreed that the WAO classification for systemic side
effects [32] should be used also for SLIT, whereas a
specific grading/classification system for local adverse
events should be applied only to SLIT [33]. This ap-
proach, if universally agreed upon, would allow a more
detailed comparison among studies, products and ad-
ministration regimens.
Reporting
There is still a large discrepancy between recommenda-
tions on how to report clinical trials and, how the re-
ports are actually made, as recommended by the
CONSORT guidelines. Unfortunately, this discrepancy is
particularly apparent for SLIT and SCIT trials, where the
adherence to CONSORT guidelines is poor [34]. Cor-
rectly and completely reporting a trial is not simply an
academic exercise. A correct reporting allows to better
reproduce (or refute) the described results, using a uni-
form methodology. Finally, since SLIT is self managed
by patients, adherence remains a primary concern, but
this has been considered only in few trials, and the re-
sults reported in experimental settings often differ from
the real-life environment [35]. Thus, reporting adher-
ence (doses taken versus prescribed) remains essential in
clinical trials, but this aspect is probably more important
in real life.
Conclusion
It is clear, looking at the published articles that SLIT is
clinically effective [7]. It is also clear that there is a large
heterogeneity among studies, mainly due to the variabil-
ity in the inclusion criteria, dose of allergen, duration,
methodological aspects, and reporting. It is also appar-
ent that studies on allergen immunotherapy require a
careful selection of patients and long duration of treat-
ment, possibly in a double blind randomized and con-
trolled fashion. It would be difficult to satisfy all the
requirements for a robust study, but some of the pos-
sible biases could be corrected, especially by developing
a consensus on the outcomes, duration of the trial, cri-
teria for patient selection, and doses to be administered.
This latter point remains of great uncertainty, since
dose-ranging studies have been performed so far with
grass, mite [36] and ragweed [37] allergens. It is also un-
clear on how early SLIT could be started, and the precise
basis for initiating it, although safety data in young chil-
dren are overall favorable for SLIT. Finally, the assessment
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to solve in clinical trials, when the real-life setting is the
usual situation.
Synopsis
The large heterogeneity of clinical trials with SLIT, par-
tially limits the robustness of the evidence provided so
far, and also affects meta-analyses. Thus, to correct this
bias, a standardization and harmonization of method-
ology is urgently needed. This concerns in particular the
following: the design, outcomes, selection of patients,
extracts, description and reporting of adverse events,
which are the most variable aspects. Efforts are currently
made by the World Allergy Organization and inter-
national societies to provide recommendations on how
to properly plan and design clinical trials, and how to
harmonize outcomes and reporting, in order to make
trials comparable each other, progressively reducing the
heterogeneity.
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